These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37217851)

  • 1. Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review.
    Shafiee A; Bahri RA; Teymouri Athar MM; Afsharrezaei F; Gholami M
    BMC Gastroenterol; 2023 May; 23(1):170. PubMed ID: 37217851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
    Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
    Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase (PDE) 5 inhibitors sildenafil, tadalafil and vardenafil impact cAMP-specific PDE8 isoforms-linked second messengers and steroid production in a mouse Leydig tumor cell line.
    Limoncella S; Lazzaretti C; Paradiso E; D'Alessandro S; Barbagallo F; Pacifico S; Guerrini R; Tagliavini S; Trenti T; Santi D; Simoni M; Sola M; Di Rocco G; Casarini L
    Mol Cell Endocrinol; 2022 Feb; 542():111527. PubMed ID: 34875337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
    Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
    Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
    Teixeira CE; Priviero FB; Webb RC
    J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
    Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
    J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
    Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG
    Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Powerful relaxation of phosphodiesterase type 4 inhibitor rolipram in the pig and human bladder neck.
    Ribeiro ASF; Fernandes VS; Martínez-Sáenz A; Martínez P; Barahona MV; Orensanz LM; Blaha I; Serrano-Margüello D; Bustamante S; Carballido J; García-Sacristán A; Prieto D; Hernández M
    J Sex Med; 2014 Apr; 11(4):930-941. PubMed ID: 24754330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release.
    Toque HA; Priviero FB; Teixeira CE; Claudino MA; Baracat JS; Fregonesi A; De Nucci G; Antunes E
    Urology; 2009 Jul; 74(1):216-21. PubMed ID: 19371941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance.
    Chhonker SK; Rawat D; Koiri RK
    J Biochem Mol Toxicol; 2022 Aug; 36(8):e23100. PubMed ID: 35608386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.
    Wang H; Ye M; Robinson H; Francis SH; Ke H
    Mol Pharmacol; 2008 Jan; 73(1):104-10. PubMed ID: 17959709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.
    Chen JJ; Sun YL; Tiwari AK; Xiao ZJ; Sodani K; Yang DH; Vispute SG; Jiang WQ; Chen SD; Chen ZS
    Cancer Sci; 2012 Aug; 103(8):1531-7. PubMed ID: 22578167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets.
    Toque HA; Teixeira CE; Priviero FB; Morganti RP; Antunes E; De Nucci G
    Br J Pharmacol; 2008 Jun; 154(4):787-96. PubMed ID: 18536732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
    Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
    J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal restoration by phosphodiesterase 5 inhibitors in osteopenic mice: Evidence of osteoanabolic and osteoangiogenic effects of the drugs.
    Pal S; Rashid M; Singh SK; Porwal K; Singh P; Mohamed R; Gayen JR; Wahajuddin M; Chattopadhyay N
    Bone; 2020 Jun; 135():115305. PubMed ID: 32126313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDE5 inhibitors and male reproduction: Is there a place for PDE5 inhibitors in infertility clinics or andrology laboratories?
    Dimitriadis F; Kaltsas A; Zachariou A; Mamoulakis C; Tsiampali C; Giannakis I; Paschopoulos M; Papatsoris A; Loutradis D; Tsounapi P; Takenaka A; Sofikitis N
    Int J Urol; 2022 Dec; 29(12):1405-1418. PubMed ID: 36194789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.